One sentence summary – Generative AI, Moderna’s mRNA technology, and the UK’s Isambard-AI supercomputer are making significant strides in their respective fields, with generative AI being increasingly adopted across industries, Moderna exploring machine learning for potential cancer treatments, and the UK government investing in Isambard-AI to harness the potential of artificial intelligence.
At a glance
- Generative AI is increasingly adopted across industries for content generation and real-time interactions.
- Generative AI enables live personalization and enhances customer experiences.
- Moderna explores machine learning for potential cancer treatments using mRNA technology.
- Isambard-AI supercomputer is being constructed by the UK government to advance AI research.
- These technologies have the potential to transform industries, improve healthcare outcomes, and drive innovation.
The details
Generative AI, Moderna’s mRNA technology, and the UK’s Isambard-AI supercomputer are making significant strides in their respective fields.
This news brief delves into the transformative power of generative AI, Moderna’s machine learning approach to cancer treatment, and the UK government’s investment in Isambard-AI to harness the potential of artificial intelligence.
Generative AI Adoption
Generative AI is increasingly adopted across industries.
This adoption is driven by executives seeking innovative use cases and faster development compared to traditional AI methods.
Generative AI is effective in content generation and real-time interactions such as chatbots and knowledge search solutions.
The architecture behind generative AI use cases is easy to implement, especially with abundant source material.
Generative AI enables live personalization and enhances customer experiences.
However, responsible and ethical AI practices are crucial to prevent misuse.
This necessitates a company-wide policy and thorough testing strategy.
Scaling generative AI can be challenging due to costs, particularly with compute-intensive large models.
Despite these challenges, the significant production enhancement and customer service returns make the compute investment worthwhile.
Moderna’s mRNA Technology
Moderna, known for developing a COVID-19 mRNA vaccine, explores machine learning for potential cancer treatments.
Their algorithm identifies genetic mutations in tumors, allowing the immune system to target cancer cells specifically.
Using mRNA, the selected mutation is coded into a vaccine to re-educate the immune system and combat cancer effectively.
While treatments are personalized, the algorithm can benefit groups of patients.
Moderna utilizes its proprietary chatbot, M Chat, similar to ChatGPT, to assist employees and keep data proprietary.
They also have an AI academy to educate employees on data science, algorithms, and prompt writing.
UK’s Isambard-AI Supercomputer
The UK government is constructing Isambard-AI, a powerful supercomputer located at the University of Bristol.
It aims to be one of Europe’s most potent supercomputers, benefiting industry experts and researchers in AI development.
Isambard 3, another supercomputer for climate science and medical research, will be activated soon.
Hardware details for Isambard-AI have not been disclosed, but Isambard 3 consists of 384 Arm-based Nvidia Grace CPU Superchips.
Universities such as Bath, Cardiff, and Exeter will also have access to Isambard-AI and Isambard 3.
The UK government has allocated $1.1 billion to enhance the country’s computing capacity and develop AI work.
Yoshua Bengio, an AI luminary, is advising the UK Prime Minister on next-gen AI models, highlighting the government’s commitment.
Generative AI continues to revolutionize various industries, while Moderna’s mRNA technology offers promising avenues for personalized cancer treatment.
The UK government’s investment in Isambard-AI showcases its dedication to advancing AI research.
As these technologies progress, they hold the potential to transform industries, improve healthcare outcomes, and drive innovation to new heights.
Article X-ray
Here are all the sources used to create this article:
A futuristic robot holding a DNA strand and a British flag.
This section links each of the article’s facts back to its original source.
If you have any suspicions that false information is present in the article, you can use this section to investigate where it came from.
| venturebeat.com |
|---|
| – Generative AI is becoming ubiquitous across industries and organizations need to understand its transformative power. |
| – Adoption rates of generative AI are increasing, driven by executives eager to embrace new use cases and innovate. |
| – Generative AI requires less data and is faster and easier to develop and launch compared to traditional AI approaches. |
| – Generative AI is effective in batch-oriented content generation and real-time interactions such as chatbots and knowledge search solutions. – |
| The architecture behind generative AI use cases is easy to implement, especially with a lot of source material available. |
| – Generative AI can deliver live personalization and enhance customer experiences. – Real-time generative AI requires guardrails to prevent misuse and ensure responsible and ethical AI practices. |
| – Companies need to have a company-wide policy on responsible and ethical AI and a thorough testing strategy. |
| – Scaling generative AI across the organization can be challenging due to cost, particularly compute costs of large models. – |
| The compute investment in generative AI is worthwhile due to the significant returns it offers in production enhancement and customer service. |
| – Generative AI provides instantaneous and engaging interactions, offering frictionless and instant gratification to end customers. |
| aibusiness.com |
|---|
| – Moderna is known for developing a COVID-19 vaccine using messenger RNA (mRNA) technology. – Moderna’s CEO, Stephane Bancel, believes that their machine learning approach to drug development could potentially treat cancer. |
| – Cancer is a disease caused by mutated DNA, and the immune system is designed to attack cancer cells. |
| – Moderna aims to use its algorithm to identify genetic mutations in tumors and target only cancer cells, not healthy ones. – |
| The selected mutation is coded into mRNA and introduced as a vaccine to help the immune system recognize and attack cancer cells. – |
| The mRNA technology aims to reset the immune system to effectively combat cancer. |
| – Moderna believes that re-educating the immune system is the key to curing cancer. – |
| While mRNA treatments are personalized for each patient, the algorithm can be expanded to benefit groups of patients. |
| – Moderna has developed its own chatbot called M Chat, similar to ChatGPT, to keep its data proprietary and assist employees with productivity. |
| – Moderna has an AI academy to teach employees about data science and algorithms, and they are developing classes for prompt writing. |
| aibusiness.com |
|---|
| – The UK government is building a new supercomputer in Bristol, England. – |
| The supercomputer, named Isambard-AI, will be housed at the University of Bristol. – Isambard-AI is expected to be one of the most powerful supercomputers in Europe. |
| – It will help industry experts and researchers harness the potential of AI. – |
| The University of Bristol already hosts the UK Center for Doctoral Training in Interactive Artificial Intelligence. |
| – Isambard 3, a supercomputer for climate science and medical research, will also be switched on later this year. |
| – |
| The hardware details for Isambard-AI have not been disclosed. |
| – Isambard 3 cluster consists of 384 Arm-based Nvidia Grace CPU Superchips with around 55,000 cores. – |
| Other local universities, including Bath, Cardiff, and Exeter, will have access to Isambard-AI and Isambard 3. – Isambard-AI will be one of the world’s first large-scale, open AI supercomputers. – |
| The UK government has allocated $1.1 billion to boost the country’s computing capacity. – |
| The Isambard-AI reveal is part of the UK government’s efforts to develop AI work. – Yoshua Bengio, an AI luminary, is advising the UK Prime Minister on next-gen AI models. |
English 
Portuguese 
Turkish 
Chinese 
German